Cell Reports (Jun 2019)

Activation of Mevalonate Pathway via LKB1 Is Essential for Stability of Treg Cells

  • Maheshwor Timilshina,
  • Zhiwei You,
  • Sonja M. Lacher,
  • Suman Acharya,
  • Liyuan Jiang,
  • Youra Kang,
  • Jung-Ae Kim,
  • Hyeun Wook Chang,
  • Keuk-Jun Kim,
  • Byoungduck Park,
  • Jae-Hyoung Song,
  • Hyun-Jeong Ko,
  • Yun-Yong Park,
  • Min-Jung Ma,
  • Mahesh Raj Nepal,
  • Tae Cheon Jeong,
  • Yeonseok Chung,
  • Ari Waisman,
  • Jae-Hoon Chang

Journal volume & issue
Vol. 27, no. 10
pp. 2948 – 2961.e7

Abstract

Read online

Summary: The function of regulatory T (Treg) cells depends on lipid oxidation. However, the molecular mechanism by which Treg cells maintain lipid metabolism after activation remains elusive. Liver kinase B1 (LKB1) acts as a coordinator by linking cellular metabolism to substrate AMP-activated protein kinase (AMPK). We show that deletion of LKB1 in Treg cells exhibited reduced suppressive activity and developed fatal autoimmune inflammation. Mechanistically, LKB1 induced activation of the mevalonate pathway by upregulating mevalonate genes, which was essential for Treg cell functional competency and stability by inducing Treg cell proliferation and suppressing interferon-gamma and interleukin-17A expression independently of AMPK. Furthermore, LKB1 was found to regulate intracellular cholesterol homeostasis and to promote the mevalonate pathway. In agreement, mevalonate and its metabolite geranylgeranyl pyrophosphate inhibited conversion of Treg cells and enhanced survival of LKB1-deficient Treg mice. Thus, LKB1 is a key regulator of lipid metabolism in Treg cells, involved in optimal programming of suppressive activity, immune homeostasis, and tolerance. : Timilshina et al. show that the LKB1-mediated mevalonate pathway is required for proper function and stability of Treg cells. These data provide mechanistic insight into the lipid metabolic programs that promote immune homeostasis and tolerance and suggest that lipid metabolism is a possible therapeutic target for pharmacological manipulation of Treg biology. Keywords: LKB1, Treg cells, mevalonate pathway, Treg stability, GGPP, autoimmune disease